Stock Scorer

4D Molecular Therapeutics, Inc. (FDMT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

-30M 0 30M 60M 90M Q3 '21: 1.4M Q4 '21: 92K Q1 '22: 1.2M Q2 '22: 162K Q3 '22: 500K Q4 '22: 1.2M Q1 '23: 298K Q2 '23: 239K Q3 '23: 20.2M Q4 '23: -19K Q1 '24: 28K Q2 '24: 5K Q3 '24: 3K Q4 '24: 1K Q1 '25: 14K Q2 '25: 15K Q3 '25: 90K Q4 '25: 85.1M Q1 '26: 3M Q2 '26: 3.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -22.7M Q4 '21: -24.8M Q1 '22: -26.4M Q2 '22: -28.4M Q3 '22: -26.5M Q4 '22: -28.7M Q1 '23: -30.1M Q2 '23: -32.1M Q3 '23: -14M Q4 '23: -36.7M Q1 '24: -38.1M Q2 '24: -42.5M Q3 '24: -51.1M Q4 '24: -56.1M Q1 '25: -53.6M Q2 '25: -59.5M Q3 '25: -61.2M Q4 '25: 14.7M Q1 '26: -73.6M Q2 '26: -77M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -22.2M Q4 '21: -25.1M Q1 '22: -26.3M Q2 '22: -28.1M Q3 '22: -25.7M Q4 '22: -27.4M Q1 '23: -28.7M Q2 '23: -29.6M Q3 '23: -10.3M Q4 '23: -32.3M Q1 '24: -32.4M Q2 '24: -35M Q3 '24: -43.8M Q4 '24: -49.7M Q1 '25: -48M Q2 '25: -54.7M Q3 '25: -56.9M Q4 '25: 19.4M Q1 '26: -68.8M Q2 '26: -72.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -15.7M Q4 '21: -21.8M Q1 '22: -23.6M Q2 '22: -19.9M Q3 '22: -21M Q4 '22: -22.2M Q1 '23: -27.9M Q2 '23: -22.1M Q3 '23: -1.2M Q4 '23: -24.6M Q1 '24: -29.1M Q2 '24: -30.2M Q3 '24: -29.4M Q4 '24: -45.9M Q1 '25: -47.8M Q2 '25: -43.4M Q3 '25: -46.5M Q4 '25: 28.6M Q1 '26: -68.1M Q2 '26: -70M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '21: -16M Q2 '21: -16.9M Q3 '21: -18.4M Q4 '21: -26.9M Q1 '22: -30M Q2 '22: -22M Q3 '22: -23M Q4 '22: -23.3M Q1 '23: -28.9M Q2 '23: -22.9M Q3 '23: -1.6M Q4 '23: -25.2M Q1 '24: -29.8M Q2 '24: -30.6M Q3 '24: -31.2M Q4 '24: -46.8M Q1 '25: -48.4M Q2 '25: -43.4M Q3 '25: -46.6M Q4 '25: 28.5M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 26.7M Q3 '21: 27M Q1 '22: 32.2M Q2 '22: 32.3M Q3 '22: 32.4M Q1 '23: 32.7M Q2 '23: 38.3M Q3 '23: 42.3M Q1 '24: 49.3M Q2 '24: 55.3M Q3 '24: 55.6M Q1 '25: 55.7M Q2 '25: 55.9M Q3 '25: 56.1M Q1 '26: 68.1M Q2 '26: 70.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -3.56 Q4 '21: -2.56 Q1 '22: -2.77 Q2 '22: -3.36 Q3 '22: -3.33 Q4 '22: -3.32 Q1 '23: -3.38 Q2 '23: -3.28 Q3 '23: -2.73 Q4 '23: -2.66 Q1 '24: -2.44 Q2 '24: -2.30 Q3 '24: -2.85 Q4 '24: -2.98 Q1 '25: -3.18 Q2 '25: -3.53 Q3 '25: -3.75 Q4 '25: -2.42 Q1 '26: -2.57 Q2 '26: -2.63 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for FDMT: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.